Microtubule inhibitor-based antibody–drug conjugates for cancer therapy

@inproceedings{Klute2014MicrotubuleIA,
  title={Microtubule inhibitor-based antibody–drug conjugates for cancer therapy},
  author={Kelsey A Klute and Eleni Nackos and Shinsuke Tasaki and Daniel P Nguyen and Neil Harrison Bander and Scott T Tagawa},
  booktitle={OncoTargets and therapy},
  year={2014}
}
The specificity of monoclonal antibodies represents a potential therapeutic advantage, but their use as single agents in oncology has proven limited to date. The development of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect of chemotherapy, leading to enhanced cytotoxicity in target cells and limiting toxicity to normal tissue. Microtubules represent a validated oncologic target in a range of tumor types, with a number… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 89 REFERENCES

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

  • Hoffman-La Roche
  • Available from: http://clinicaltrials.gov/show…
  • 2014
1 Excerpt

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

  • Hoffmann-La Roche
  • Available from: http://clinicaltrials.gov/ct2…
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…